netbook
desktop
mobile
tablet-landscape
tablet
phone-landscape
phone
Research to Prevent Blindness

Reversing Retinal Degenerative Diseases: We’re One Step Closer

Degenerative disorders affecting the retinal pigment epithelium (RPE), such as age-related macular degeneration and autosomal recessive bestrophinopathy, can ultimately lead to blindness. Some of these life-changing disorders are the result of mutations in a single gene, called BEST1.

Although the genetic defect in BEST1 was identified almost two decades ago, its physiological role—how it does what it does, was unclear. Now, researchers from Columbia University and University of Rochester have used a novel approach to solve this mystery. Today, they published their pioneering study in the journal eLife

RPB Physician-Scientist Awardee Stephen H. Tsang, MD, PhD, of Columbia University, at work in his lab.

The researchers created a “disease-in-a-dish,” meaning that they coaxed skin cells taken from an adult patient first back into an embryonic-like state (called induced pluripotent stem cells, or iPSCs) and then into RPE cells to create a model of retinal degenerative disease. Then they assessed physiological properties of the RPE cells carrying normal or mutated BEST1 via innovative, interdisciplinary approaches to pinpoint the exact role of the BEST1 gene.

The researchers were also able to show that RPE cells that carry the BEST1 gene mutations, which are the same cells that are damaged by degenerative diseases, can have their damage reversed by providing healthy copies of the BEST1 gene (through viral gene supplementation, which uses a specially selected virus to “carry” new genes into the cells).

“Our team provided evidence that autosomal recessive bestrophinopathy is a ‘chloride channelopathy’ and is a treatable disorder,” said RPB Physician-Scientist Awardee Stephen H. Tsang, MD, PhD, Associate Professor of Ophthalmology and Associate Professor of Pathology and Cell Biology at Columbia University, and Tingting Yang, PhD, Assistant Professor of Pharmacology and Physiology at University of Rochester.

 

 

Related News: Feature Story, Gene Therapy, Macular Degeneration, Retina Disorders , Stem Cell Therapy, Top Story

RPB logo

Research to Prevent Blindness and The Glaucoma Foundation Offer Critical Funding for Early-Career Vision Scientists

The Career Advancement Awards—one focused specifically on glaucoma research—support novel science related to eye diseases by up-and-coming researchers.

Read More

 
Event photo
Watch The Video

RPB Hosts Virtual Event On Diabetic Retinopathy

RPB grantees provide expert advice on DR as part of the "Lunch & Learn" series.

Read More

 
RPB logo

New Fellowships Support Under-Represented Minorities in Glaucoma Research

The Glaucoma Foundation and Research to Prevent Blindness have partnered to provide five fellowships in 2021 to increase innovation and diversity in glaucoma research.

Read More

 
Watch The Video

RPB Hosts Virtual AMD Event

RPB grantees provide expert advice on AMD as part of the "Lunch & Learn" series.

Read More

 
Glaucoma event banner
Watch The Video

RPB Hosts Virtual Glaucoma Event

RPB grantees provide expert advice on glaucoma in the first event of the "Lunch & Learn" series.

Read More

 
scEYEnce campaign image

RPB and Partners Launch the scEYEnce Campaign

This new media campaign shines a spotlight on the powerful benefits of vision research.

Read More

 

Subscribe

Get our email updates filled with the latest news from our researchers about preventing vision loss, treating eye disease and even restoring sight. Unsubscribe at any time. Under our privacy policy, we'll never share your contact information with a third party.